Evaluating Kobayashi and Kawanet Scores for IVIG Resistance in Children with Kawasaki Disease in Europe and North India
Led by Meyer Children's Hospital IRCCS · Updated on 2025-09-29
103
Participants Needed
27
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
Kawasaki disease KD is a leading cause of acquired heart disease in children, particularly in developed countries. The study evaluates the performance of two scoring systems, Kobayashi and Kawanet, which aim to predict resistance to intravenous immunoglobulin IVIG treatment in KD patients. Resistance to IVIG occurs in 10-20% of patients and poses a significant risk for cardiac complications like coronary aneurysms. The study focuses on a multi-center European and North Indian cohort to assess the sensitivity and specificity of these scores in non-Asian populations.
This observational study does not involve experimental treatments but monitors KD patients aged 1 to 17 years diagnosed according to American Heart Association AHA criteria. It compares the Kobayashi and Kawanet IVIG resistance scores to determine their accuracy in predicting which patients may not respond to standard IVIG therapy. The study spans an average duration of one year during which patients are observed for IVIG resistance.
Participants will be followed up to measure the rate and percentage of IVIG resistance throughout the study period. Data collection includes clinical evaluations and monitoring of patient outcomes related to cardiac health. The study aims to validate the scoring systems for better prediction of treatment resistance, which may help guide future treatment decisions. Participants will be involved in regular assessments over the year-long study period to track their response and health status.
CONDITIONS
Brief Title
European and North Indian Cohort of KaWasaki dIsease
Research Team
G
Gabriele Simonini
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of Kawasaki disease according to the American Heart Association criteria
You will not qualify if you...
Patients who do not meet the criteria for Kawasaki disease
Patients for which an alternative infectious diagnosis was not investigated and/or excluded
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Long-term Monitoring
Duration - Approximately 1 year
Participants diagnosed with Kawasaki disease are observed to assess IVIG resistance over an average of 1 year.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Comparing Anakinra and Intravenous Immunoglobulin Retreatments for Children With Kawasaki Disease Who Did Not Respond to Initial IVIG
Study of Cardiovascular Risk in Children and Young Adults With Chronic Health Conditions
Evaluating Kobayashi and Kawanet Scores for IVIG Resistance in Children with Kawasaki Disease in Europe and North India
Evaluating the Kawasaki MATCH Machine-Learning Tool to Detect Kawasaki Disease in Children and Teens
Pilot Study of Model-Informed Rivaroxaban Dose Adjustment for Chinese Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
Study of How Understudied Drugs Act in Children and Young Adults Receiving Routine Medical Care
Study of Rivaroxaban Treatment and Drug Levels in Chinese Children Aged 2 to 18 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
Coordination of Rare Diseases at Sanford Registry for Individuals with Rare and Undiagnosed Conditions
Study Comparing Rivaroxaban and Warfarin to Prevent Blood Clots in Children Over 2 Years Old with Giant Coronary Artery Aneurysms After Kawasaki Disease
Atorvastatin Treatment in Children Aged 2 to 18 with Acute Kawasaki Disease and Coronary Artery Abnormalities
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Predictive value for intravenous immunoglobulin resistance of Kobayashi and Kawanet scores in 722 children with Kawasaki disease across diverse ethnic backgrounds (KIWI study): an international cohort study.
Maria Vincenza Mastrolia, Vignesh Pandiarajan, Marco Cattalini...